LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
82.77
+0.06 (+0.07%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close82.71
Open82.79
Bid0.00 x 800
Ask0.00 x 800
Day's Range82.59 - 83.47
52 Week Range73.69 - 89.09
Volume2,338,143
Avg. Volume4,062,887
Market Cap84.482B
Beta0.24
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.25 (2.77%)
Ex-Dividend Date2018-02-14
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Sue Mahony to Retire as President of Lilly Oncology
    PR Newswire5 days ago

    Sue Mahony to Retire as President of Lilly Oncology

    INDIANAPOLIS, May 23, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that Sue Mahony, Ph.D., senior vice president of Lilly and president of Lilly Oncology, will retire at the end of August after 18 years of service with the company. Mahony is also a member of Lilly's executive committee. "On behalf of our executive team and the company, I want to thank Sue for her leadership over the past 18 years," said David A. Ricks, Lilly's chairman and chief executive officer.

  • Elanco, Heifer International 10-Year Effort Breaks the Cycle of Hunger for 160,000 Families
    PR Newswire5 days ago

    Elanco, Heifer International 10-Year Effort Breaks the Cycle of Hunger for 160,000 Families

    GREENFIELD, Ind., May 23, 2018 /PRNewswire/ -- Elanco Animal Health, a division of Eli Lilly and Company (LLY), and Heifer International mark a 10-year milestone in their journey that shares the upcoming World Hunger Day mission – empowering  people to create a food secure world. Since 2008, Elanco and its employees have joined forces to give nearly $5 million to Heifer International's efforts to achieve food security across the globe. Through eight projects, Elanco and Heifer International have created more access to meat, milk and eggs through placing 35,600 animals, including cows, swine, poultry, goats, sheep and chickens in Zambia, Cambodia, India, China, Ecuador and Bangladesh.

  • Lilly's Taltz® (ixekizumab) Receives the First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving the Genital Area
    PR Newswire6 days ago

    Lilly's Taltz® (ixekizumab) Receives the First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving the Genital Area

    "Up to 63 percent of psoriasis patients will be impacted by psoriasis involving the genital area over the course of their disease," said Pete Salzmann, vice president, Lilly Immunology. "However, there remains a serious unmet need for patients seeking treatment options.

  • ACCESSWIRE7 days ago

    Bristol-Myers Squibb and Three Additional Stocks Under Scanner in the Drug Makers Space

    Major equities: AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Co. (NYSE: BMY), Eli Lilly and Co. (NYSE: LLY), and GW Pharmaceuticals PLC (NASDAQ: GWPH). All you have to do is sign up today for this free limited time offer by clicking the link below.

  • ACCESSWIRE11 days ago

    Wired News – Eli Lilly’s Galcanezumab Met Primary Endpoint in Phase-3 Study for Prevention of Episodic Cluster Headache

    LONDON, UK / ACCESSWIRE / May 17, 2018 / If you want access to our free research report on Eli Lilly and Co. (NYSE: LLY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=LLY as the Company's latest news hit the wire. On May 15, 2018, the Company announced that a Phase-3 study evaluating galcanezumab in patients with episodic cluster headache met its primary endpoint, demonstrating statistically significant differences in the reduction of weekly cluster headache attacks compared to placebo across weeks one to three of the two-month, double-blind treatment period. There were also a statistically significantly greater percentage of patients treated with galcanezumab who achieved at least a 50% reduction in weekly cluster headache attacks compared to placebo at Week 3, the gated secondary endpoint.

  • Lilly Data at ASCO Illustrate Patient-Driven Advances in Cancer Care
    PR Newswire11 days ago

    Lilly Data at ASCO Illustrate Patient-Driven Advances in Cancer Care

    First presentation of findings from the ramucirumab REACH-2 study - the first positive Phase 3 hepatocellular carcinoma trial in a biomarker-selected population Research across the MONARCH clinical development ...

  • Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache
    PR Newswire13 days ago

    Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache

    INDIANAPOLIS, May 15, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that galcanezumab met its primary endpoint in a Phase 3 study of patients with episodic cluster headache, demonstrating statistically significant differences in the reduction of weekly cluster headache attacks compared to placebo across weeks one to three of the two-month, double-blind treatment period. A statistically significantly greater percentage of patients treated with galcanezumab also achieved at least a 50 percent reduction in weekly cluster headache attacks compared to placebo at Week 3, the gated secondary endpoint. The observed safety and tolerability profile was consistent with previous studies that evaluated galcanezumab for the prevention of migraine.

  • PR Newswire14 days ago

    WeissLaw LLP: ARMO BioSciences Inc. Acquisition May Not Be In The Best Interests of ARMO shareholders

    WeissLaw is investigating whether ARMO's Board acted to maximize shareholder value prior to entering into the agreement.  Notably, at least one analyst set a target price of $75.00 per share, or $25.00 above the offer price.  Moreover, the deal is a strategic transaction that will expand LLY's drug portfolio and provide LLY a foothold in the very lucrative cancer immunotherapy industry.

  • Lilly to Acquire AurKa Pharma
    PR Newswire14 days ago

    Lilly to Acquire AurKa Pharma

    INDIANAPOLIS, May 14, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced an agreement to acquire AurKa Pharma, Inc., a company established by TVM Capital Life Science to develop oncology compound AK-01, an Aurora kinase A inhibitor that was originally discovered at Lilly. The compound is a potential first-in-class asset that AurKa Pharma is studying in Phase 1 clinical trials in multiple types of solid tumors. AurKa Pharma's asset, AK-01, has been shown to be highly selective for Aurora A, with potential clinical benefit observed in Phase 1 studies.

  • Lilly to Participate in UBS Global Healthcare Conference
    PR Newswire17 days ago

    Lilly to Participate in UBS Global Healthcare Conference

    INDIANAPOLIS , May 11, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 22, 2018 . Enrique Conterno , senior vice president of Lilly ...

  • Lilly Announces Agreement To Acquire ARMO BioSciences
    PR Newswire18 days ago

    Lilly Announces Agreement To Acquire ARMO BioSciences

    INDIANAPOLIS and REDWOOD CITY, Calif., May 10, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and ARMO BioSciences, Inc. (ARMO) today announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion, in an all-cash transaction. ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates designed to activate the immune system of cancer patients to recognize and eradicate tumors.

  • Elanco Animal Health Announces Addition of General Counsel
    PR Newswire18 days ago

    Elanco Animal Health Announces Addition of General Counsel

    Indiana-based company adds Michael-Bryant Hicks to leadership team GREENFIELD, Ind. , May 10, 2018 /PRNewswire/ -- Today, Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), named Michael-Bryant ...

  • Lilly Declares Second-Quarter 2018 Dividend
    PR Newswire21 days ago

    Lilly Declares Second-Quarter 2018 Dividend

    INDIANAPOLIS , May 7, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2018 of $0.5625 per share on outstanding common ...

  • Lilly and Local Partners Launch Diabetes Prevention and Management Pilot in Three Underserved Neighborhoods in Indianapolis
    PR Newswire27 days ago

    Lilly and Local Partners Launch Diabetes Prevention and Management Pilot in Three Underserved Neighborhoods in Indianapolis

    INDIANAPOLIS, May 1, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and Indiana University's Richard M. Fairbanks School of Public Health at IUPUI announced today the launch of a new neighborhood-based, data-driven pilot in Indianapolis to help address the high incidence of diabetes. Building on similar efforts Lilly has developed in lower-income communities in Mexico, India and South Africa, the $7 million, five-year program will focus on three Indianapolis neighborhoods with significant health disparities and high rates of diabetes: the Coalition of Northeast Neighborhoods, Northwest Neighborhood and Near Westside Neighborhood.

  • Leena Gandhi, M.D., Ph.D., to Lead Lilly Oncology Immuno-Oncology Medical Development
    PR Newswire28 days ago

    Leena Gandhi, M.D., Ph.D., to Lead Lilly Oncology Immuno-Oncology Medical Development

    Dr. Gandhi is currently the Director of Thoracic Medical Oncology and an associate professor of medicine at the New York University (NYU) School of Medicine. After joining Lilly, she will lead a team of scientists that oversees the Lilly Oncology immunotherapy portfolio.

  • Lilly to Participate in Bank of America Merrill Lynch Health Care Conference
    PR Newswirelast month

    Lilly to Participate in Bank of America Merrill Lynch Health Care Conference

    INDIANAPOLIS , April 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Merrill Lynch 2018 Health Care Conference on Wednesday, May 16, 2018 . Christi Shaw ...

  • Lilly and China's NCCD announce collaboration to advance scientific understanding and care for people living with diabetes and cardiovascular disease
    PR Newswirelast month

    Lilly and China's NCCD announce collaboration to advance scientific understanding and care for people living with diabetes and cardiovascular disease

    - Collaboration between China's National Center for Cardiovascular Diseases and Lilly aims to improve care for people living with Type 2 diabetes in China - The Lilly and NCCD collaboration will address ...

  • Lilly Reports Strong First-Quarter 2018 Results, Raises EPS Guidance
    PR Newswirelast month

    Lilly Reports Strong First-Quarter 2018 Results, Raises EPS Guidance

    - First-quarter 2018 revenue increased 9 percent, driven primarily by the increased demand for new pharmaceutical products, while operating expenses declined 5 percent. - First-quarter 2018 earnings per ...

  • AAN 2018: Lilly's Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies
    PR Newswirelast month

    AAN 2018: Lilly's Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies

    INDIANAPOLIS, April 24, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today results from a post-hoc subgroup analysis which demonstrated efficacy of galcanezumab in patients with episodic and chronic migraine who previously failed to respond to two or more preventive therapies. Detailed results from a new subgroup analysis of three Phase 3 studies (EVOLVE-1, EVOLVE-2 and REGAIN) evaluating galcanezumab will be presented today as part of the "Best of Headache" platform session at the American Academy of Neurology (AAN) annual meeting in Los Angeles. The U.S. Food and Drug Administration (FDA) is reviewing galcanezumab for the prevention of migraine in adults.

  • FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis
    PR Newswirelast month

    FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis

    INDIANAPOLIS, April 23, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced today that the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee recommended approval of the 2-mg dose of baricitinib, a once-daily oral medication for the treatment of moderately-to-severely active rheumatoid arthritis (RA) for adult patients who have had an inadequate response or intolerance to methotrexate. While the Advisory Committee unanimously supported the efficacy of the 4-mg dose of baricitinib, it did not recommend approval of the 4-mg dose of baricitinib for the proposed indication based on the adequacy of the safety and benefit-risk profiles.

  • Elanco Announces Addition of Chief Financial Officer
    PR Newswirelast month

    Elanco Announces Addition of Chief Financial Officer

    Christopher Jensen to join Indiana-based Animal Health Company's Leadership Team GREENFIELD, Ind. , April 23, 2018 /PRNewswire/ -- Today, Elanco Animal Health, a division of Eli Lilly and Company (NYSE: ...

  • Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer
    PR Newswirelast month

    Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer

    Significant improvement in primary endpoint of progression-free survival previously reported; Improvement in objective response rate observed; Positive trend in overall survival did not reach statistical ...

  • Lilly to Present Phase 3 Data at AAN 2018 Reinforcing Commitment to New, Innovative Therapies in Migraine
    PR Newswirelast month

    Lilly to Present Phase 3 Data at AAN 2018 Reinforcing Commitment to New, Innovative Therapies in Migraine

    INDIANAPOLIS, April 20, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today it will present Phase 3 data for galcanezumab and lasmiditan, two investigational treatments for migraine, at the American Academy of Neurology (AAN) annual meeting taking place April 21-27 in Los Angeles. Lilly will highlight a new analysis from three Phase 3 studies (EVOLVE-1, EVOLVE-2 and REGAIN) evaluating galcanezumab in patients who previously failed two or more preventive therapies as part of the "Best in Headache" platform session on Tuesday, April 24. Galcanezumab is a once-monthly, self-administered calcitonin gene-related peptide (CGRP) antibody currently under review by the U.S. Food and Drug Administration (FDA) for the prevention of migraine in adults.

  • Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease
    PR Newswirelast month

    Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease

    RIDGEFIELD, Conn. and INDIANAPOLIS, April 16, 2018 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (LLY) today announced an academic collaboration with the University of Oxford to investigate the effects of Jardiance® on the progression of kidney disease and the occurrence of cardiovascular death, in adults with established chronic kidney disease with and without diabetes. EMPA-KIDNEY will be independently conducted, analyzed and reported by the Medical Research Council Population Health Research Unit at the University of Oxford (MRC PHRU), which is based in the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), in partnership with the Duke Clinical Research Institute.

  • ACCESSWIRE2 months ago

    Wired News – Eli Lilly's Phase-3 REACH-2 Study of CYRAMZA(R) Met its Primary Endpoint of Overall Survival

    Stock Monitor: China Pharma Holdings Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 6, 2018 / Active-Investors.com has just released a free research report on Eli Lilly and Co. (NYSE: LLY ) ("Eli ...